On March 1st the FDA approved a new HIV antiretroviral ODEFSEY. This medication contains the following drugs: emtricitabine 200mg, rilpivirine 25mg and tenofovir alafenamide 25mg. ODEFSEY is a fixed-dose combination indicated as a complete regimen for HIV-1 infection in patients older than 12 years as initial HIV therapy in people with no antiretroviral treatment history and an HIV viral load <100,000 copies/ml or to replace a stable antiretroviral regimen in those who are virologically suppressed. ODEFSEY contains tenofovir alafenamide the new tenofovir prodrug. Complera which has been approved by FDA since August 11, 2011 contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate 300mg.
With the approval of ODEFSEY the regimen can be used in people with kidney issues who have a creatinine clearance greater than or equal to 30ml/min.
For more information on the differences and similarities between tenofovir alafenamide and tenofovir disoproxil fumarate see our previous article HERE
Any questions about your meds always ask your doctor and pharmacist
